Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
OSE Immuno (OSE FP)
Watchlist
36
Analysis
Health Care
•
France
OSE Immunotherapeutics SA is a biotechnology company based in France, developing immunotherapy products against invasive/metastatic late-stage cancers.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
OSE Immuno
•
08 Jul 2020 16:06
•
Issuer-paid
OSE Immunotherapeutics - Encouraging data from novel preclinical projects
OSE has a well-balanced R&D pipeline in terms of technology and asset stage (from discovery to Phase III). At the American Association of...
Edison Investment Research
Follow
74 Views
Share
bullish
•
OSE Immuno
•
07 Apr 2020 22:34
•
Issuer-paid
OSE Immunotherapeutics - Positive Tedopi step 1, rethinking its future
On 1 April 2020, OSE announced that the primary endpoint was met in the predefined step 1 analysis of the Phase III Atalante 1 trial with OSE’s...
Edison Investment Research
Follow
505 Views
Share
bullish
•
OSE Immuno
•
13 Mar 2020 16:28
•
Issuer-paid
OSE Immunotherapeutics - Progress with key R&D assets
OSE has a well-balanced R&D pipeline in terms of asset stage and technology. In the near term, much of the focus is on Tedopi, an off-the-shelf...
Edison Investment Research
Follow
642 Views
Share
bullish
•
OSE Immuno
•
30 Sep 2019 22:25
•
Issuer-paid
OSE Immunotherapeutics - R&D progress triggers milestone payment windfall
OSE Immunotherapeutics now has four clinical trials running. Interim results from its Phase III Atalante 1 trial with cancer vaccine Tedopi are a...
Edison Investment Research
Follow
795 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x